News
21 May 2010
Managing both chest congestion and a sore throat has never been easier, as new DURO-TUSS™ Chesty Cough eucalyptus and menthol lozenge joins a broad and ever increasing range of DURO-TUSS™ cough medicine products, just in time for the 2010 Australian winter season. The new cool flavoured ...
19 May 2010
iNova Pharmaceuticals today announced its partner Eisai Co., Ltd. (“Eisai”) has received approval to market anti-arrhythmic Tambocor® (flecainide acetate) 50mg and 100mg tablets in Japan for the new indication of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal ...
18 March 2010
In a world first, MetroGel™ V, South Africa’s leading vaginal gel preparation, is now available over the counter (OTC) in pharmacy as a first line therapy to treat bacterial vaginosis (BV). Women now have the convenience of going to their pharmacy for advice and assistance in treating ...
18 March 2010
iNova Pharmaceuticals is launching two new Duro-Tuss products in New Zealand, further expanding its broad range of cough therapies. Duro-Tuss Chesty Cough Liquid Forte in 100mL and 200mL, combining Bromhexine hydrochloride and expectorant Guaiphenesin, clears heavy chesty coughs and is ...
17 November 2009
Perfect spring weather, cheering onlookers and cool shirts were the order of the day as 26 Team Azep iNova cyclists, in true community spirit, finished the 2009 Multiple Sclerosis (MS) 90km Gong Ride.
06 November 2009
iNova Pharmaceuticals, one of the top five fastest growing pharmaceutical companies in Australia, today unveiled increased production capacity at its world class manufacturing, laboratory and product development facility, the iNova Technology Centre, in Sydney.
20 October 2009
Community spirit was in full swing at iNova Pharmaceuticals (“iNova”), Sydney, which today hosted a Morning Tea to raise funds for Multiple Sclerosis (MS) research. “Team Azep iNova” riders were introduced, having already exceeded the initial $10,000 fundraising goal leading up to the 2009 MS ...
15 October 2009
Pharmaceutical Society of Australia (PSA) members experienced a rare opportunity this week when a group of pharmacists toured iNova Pharmaceuticals’ manufacturing, laboratory and product development facility, the iNova Technology Centre, at the company’s corporate headquarters in Sydney.
11 August 2009
iNova Pharmaceuticals (“iNova”), a company rapidly expanding in the Asia-Pacific and Southern Africa regions, today announced the signing of an exclusive agreement for a patent submitted, clinically proven novel nasal spray in the treatment of non-allergic rhinitis.
28 April 2009
iNova Pharmaceuticals (“iNova”), a company steadily growing in the Asia-Pacific and South Africa regions, has acquired the rights to a range of topical skin products within Asia, as well as a prescription pain relief medicine, under two new separate agreements.
20 January 2009
Despite the current turbulent economic climate, iNova Pharmaceuticals is continuing to accelerate its growth and development to increase company value.
29 June 2007
As one of the few pharmaceutical companies with corporate headquarters in Australia, iNova Pharmaceuticals unveiled the ambitious multi-million dollar upgrade of its manufacturing and laboratory facilities in Sydney today.
04 June 2007
A significant milestone for iNova Pharmaceuticals is the multi-million dollar re-development of our manufacturing and laboratory facilities at Thornleigh, completed in 2006.
05 December 2006
3M Pharmaceuticals Asia Pacific and Africa announced today iNova Pharmaceuticals as its new business name. This follows closure of the $455 million sale of 3M Company’s branded pharmaceutical business in Australia, New Zealand, Asia Pacific and South Africa to Australian private equity firms Archer ...